TrialGynecologic oncology2022

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.

Panagiotis A Konstantinopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.